Oncology Venture A/S – Trademark Portfolio
Entity Type: 03
Oncology Venture A/S holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 44 (Medical Services) — 4 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include DRP, ALLARITY, and ALLARITY THERAPEUTICS. The owner is based in Hørsholm.
Venlighedsvej 1
Hørsholm 2970 , DK
Showing of trademarks Trademarks
Trademark Classifications
Oncology Venture A/S's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Oncology Venture A/S have?
Oncology Venture A/S has 4 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 cancelled.
What trademark classes does Oncology Venture A/S file in?
Oncology Venture A/S files trademarks across 3 Nice Classification classes. The most active classes are Class 44 (Medical Services), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 44 covers medical services; veterinary services; hygienic and beauty care for human beings or animals.
What are Oncology Venture A/S's most well-known trademarks?
Oncology Venture A/S's registered trademark portfolio includes well-known marks such as DRP, ALLARITY, and ALLARITY THERAPEUTICS. These are among 3 currently registered trademarks in the portfolio.
What is Oncology Venture A/S's trademark registration success rate?
Oncology Venture A/S has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.